癌变·畸变·突变 ›› 2010, Vol. 22 ›› Issue (5): 386-390.doi: 10.3969/j.issn.1004-616x.2010.05.014

• 检测研究 • 上一篇    下一篇

EGFR、VEGFR1/Flt_1在未放疗和放疗后食管鳞癌组织中的表达

李启凤,吴名耀   

  • 收稿日期:2010-01-14 修回日期:2010-03-10 出版日期:2010-09-30 发布日期:2010-09-30
  • 通讯作者: 吴名耀

The expression of EGFR, VEGFR1/Flt_1 in esophageal squamous cell carcinoma tissues with or without radiotherapy

LI Qi-feng, WU Ming-yao   

  • Received:2010-01-14 Revised:2010-03-10 Online:2010-09-30 Published:2010-09-30
  • Contact: WU Ming-yao

摘要: 目的: 探讨食管鳞癌组织中内皮生长因子受体(EGFR)、血管内皮生长因子受体1(VEGFR1/Flt_1 )的表达与术前辅助放疗敏感性的关系。 方法: 采用免疫组织化学染色方法(EnVision二步法)检测40例未接受放疗和40例接受放疗后手术切除的食管鳞癌组织,以及20例切除组织的上切缘正常组织中EGFR、VEGFR1/Flt_1的表达。 结果: EGFR在正常组织中无表达,在未接受放疗食管鳞癌中的表达率为77.5%,在接受放疗后食管鳞癌中的表达率为70%,EGFR在放疗后食管鳞癌中的表达与未放疗食鳞癌的表达相比,经卡方检验其差异具有统计学意义(P<0.05)。VEGFR1/Flt_1在正常组织中阳性表达率为80%,在未接受放疗食管鳞癌中的表达率为62.5%,在接受放疗后食管鳞癌中的表达率为80%,VEGFR1/Flt_1在放疗后食管鳞癌中的表达与未放疗食管鳞癌的表达相比较,经卡方检验其差异具有统计学意义 (P<0.05)。 结论: 检测EGFR、VEGFR1/Flt_1有助于预测食管鳞癌术前放疗的疗效。

关键词: 食管鳞癌, 放射治疗, 内皮生长因子受体, 血管内皮生长因子受体1

Abstract: OBJECTIVE: To investigate the expressions of EGFR(endothelial growth factor receptor), and VEGFR1/ Flt_1(vascular endothelial growth factor receptor 1/Flt_1) in esophageal squamous cell carcinoma tissues with or without radiotherapy, and evaluate the correlation between the expressions and the sensitivity of preoperative radiotherapy. METHODS: We used immunohistochemical method(EnVision) to assess the expressions of EGFR and VEGFR1/Flt_1 in 40 squamous cell carcinomas with radiotherapy, 40 without radiotherapy, and 20 normal tissues at the proximal end of resection. RESULTS: For EGFR, there was no expression in normal esophageal tissues, but 70% and 77.5%expression in esophageal squamous cell carcinoma with and without radiotherapy, respectively (P<0.05). For VEGFR1/Flt_1, 80% expression in normal tissue was observed, while 80% and 62.5% in esophageal squamous cell carcinoma with and without radiotherapy, respectively, were found (P<0.05). CONCLUSION: EGFR, VEGFR1/Flt_1 could be used as marker for esophageal squamous cell carcinoma radiotherapy sensitivity preoperatively.

Key words: esophageal carcinoma, radiotherapy, endothelial groth factor receptor, VEGFR1/Flt_1